DailySpaceBursa Malaysia companies, read from their annual reports从年报读懂大马上市公司

TMC Life Sciences Berhad

0101 · Main Market主板(Main Market) · annual reports 2023 to 2025, 2052 entries read2023 至 2025 年报,共读出 2052 条

Revenue, 20252025 年营业额RM345.5m3.46亿令吉down 0.3% from比 2024 年减少 0.3%,当年为 RM346.4m3.46亿令吉 in 2024
Profit for the financial year, 20252025 年本财政年度盈利RM3.61m361万令吉down 91.1% from比 2024 年减少 91.1%,当年为 RM40.6m4.06千万令吉 in 2024
Net cash from operating activities, 20252025 年营运活动所得现金净额RM22.5m2.25千万令吉down 69.9% from比 2024 年减少 69.9%,当年为 RM74.8m7.48千万令吉 in 2024
Cash and bank balances, 20252025 年现金与银行结余RM109.6m1.10亿令吉down 41.9% from比 2024 年减少 41.9%,当年为 RM188.6m1.89亿令吉 in 2024

The company这家公司

TMC Life Sciences provides healthcare services, predominantly in Malaysia. Its businesses include Thomson Hospital Kota Damansara, fertility services, Thomson TCM and TMC Care Pharmacy. TMC Fertility began rebranding to Thomson Fertility in 2025.TMC Life Sciences 提供医疗服务,业务主要在马来西亚。旗下业务包括 Thomson Hospital Kota Damansara、生育医疗服务、Thomson TCM 和 TMC Care Pharmacy。TMC Fertility 于 2025 年开始更名为 Thomson Fertility。

Source: annual report 2024, pages 9, 11; annual report 2025, pages 26, 205.出处:2024 年年报第 9、11 页;2025 年年报第 26、205 页。

In 2025, hospital and ancillary services generated RM312.4 million of revenue, and clinic services generated RM23.1 million. The remaining revenue came from hospital administration fees, clinic rental income, membership fees and other sources. The report says no single customer accounted for 10% or more of annual revenue.2025 年,医院及辅助服务带来 RM312.4 million 营业额,诊所服务带来 RM23.1 million。其余营业额来自医院管理费、诊所租金、会员费及其他来源。年报表示,没有单一客户占全年营业额的 10% 或以上。

Source: annual report 2025, pages 174, 205.出处:2025 年年报第 174、205 页。

SASTERIA (M) PTE. LTD. holds 1,221,638,155 shares, or 70.13%. The largest account is UOB KAY HIAN NOMINEES (ASING) SDN. BHD., for UOB KAY HIAN PTE. LTD. for SASTERIA (M) PTE. LTD. The immediate, penultimate and ultimate holding companies are Sasteria (M) Pte. Ltd., Sasteria Pte. Ltd. and Thomson Medical Group Limited. DYAM TUNKU ISMAIL IBNI SULTAN IBRAHIM holds 133,000,000 shares, or 7.64%.SASTERIA (M) PTE. LTD. 持有 1,221,638,155 股,占 70.13%。最大的持股账户是 UOB KAY HIAN NOMINEES (ASING) SDN. BHD.,注明为 UOB KAY HIAN PTE. LTD. 代 SASTERIA (M) PTE. LTD. 持有。直接、上一级及最终控股公司分别是 Sasteria (M) Pte. Ltd.、Sasteria Pte. Ltd. 和 Thomson Medical Group Limited。DYAM TUNKU ISMAIL IBNI SULTAN IBRAHIM 持有 133,000,000 股,占 7.64%。

Source: annual report 2025, pages 142, 207, 209.出处:2025 年年报第 142、207、209 页。

The 2025 largest-holder list includes two pledged securities accounts for SIOW WONG YEN @ SIOW KWANG HWA: ALLIANCEGROUP NOMINEES (TEMPATAN) SDN. BHD. holds 6,500,000 shares, or 0.37%, and MERCSEC NOMINEES (TEMPATAN) SDN. BHD. holds 4,537,800 shares, or 0.26%.2025 年大股东名单列有两个为 SIOW WONG YEN @ SIOW KWANG HWA 开设的抵押证券账户:ALLIANCEGROUP NOMINEES (TEMPATAN) SDN. BHD. 持有 6,500,000 股,占 0.37%;MERCSEC NOMINEES (TEMPATAN) SDN. BHD. 持有 4,537,800 股,占 0.26%。

Source: annual report 2025, page 207.出处:2025 年年报第 207 页。

Other pledged securities accounts in the 2025 list are MERCSEC NOMINEES (TEMPATAN) SDN. BHD. for WONG FUEI BOON, with 4,005,000 shares (0.23%); AFFIN HWANG NOMINEES (TEMPATAN) SDN. BHD. for YEW BOON HEAN, with 2,000,000 shares (0.11%); PUBLIC NOMINEES (TEMPATAN) SDN. BHD. for YONG MEW SENG, with 1,997,600 shares (0.11%); HLB NOMINEES (TEMPATAN) SDN. BHD. for WONG TAK KEONG, with 1,543,000 shares (0.09%); and ALLIANCEGROUP NOMINEES (TEMPATAN) SDN. BHD. for ONG YOONG NYOCK, with 1,387,600 shares (0.08%).2025 年名单中的其他抵押证券账户包括:MERCSEC NOMINEES (TEMPATAN) SDN. BHD. 为 WONG FUEI BOON 持有 4,005,000 股(0.23%);AFFIN HWANG NOMINEES (TEMPATAN) SDN. BHD. 为 YEW BOON HEAN 持有 2,000,000 股(0.11%);PUBLIC NOMINEES (TEMPATAN) SDN. BHD. 为 YONG MEW SENG 持有 1,997,600 股(0.11%);HLB NOMINEES (TEMPATAN) SDN. BHD. 为 WONG TAK KEONG 持有 1,543,000 股(0.09%);ALLIANCEGROUP NOMINEES (TEMPATAN) SDN. BHD. 为 ONG YOONG NYOCK 持有 1,387,600 股(0.08%)。

Source: annual report 2025, pages 208, 209.出处:2025 年年报第 208、209 页。

Dr. Heng Jun Li Melvin became Acting Group Chief Executive Officer on 29 January 2024. Dato’ Dr. Adzuan Abdul Rahman joined as Group Chief Executive Officer on 10 February 2025. The 2025 directors' report records Cheah Ho Chee as retired on 6 November 2024 and Wan Nadiah Binti Wan Mohd Abdullah Yaakob as removed on 9 December 2024.Dr. Heng Jun Li Melvin 于 2024 年 1 月 29 日出任代理集团首席执行官。Dato’ Dr. Adzuan Abdul Rahman 于 2025 年 2 月 10 日加入,担任集团首席执行官。2025 年董事报告记载,Cheah Ho Chee 于 2024 年 11 月 6 日退休,Wan Nadiah Binti Wan Mohd Abdullah Yaakob 于 2024 年 12 月 9 日被免职。

Source: annual report 2024, page 100; annual report 2025, pages 117, 143.出处:2024 年年报第 100 页;2025 年年报第 117、143 页。

Revenue by source, 20252025 年各来源营业额

Hospital and ancillary services: 90.4%Hospital administration fee: 0.8%Clinic rental income: 0.8%Clinic services: 6.7%Membership fees: 0.0%Others: 1.4%
Hospital and ancillary services 90.4%医院及辅助服务 90.4%Hospital administration fee 0.8%医院管理费 0.8%Clinic rental income 0.8%诊所租金收入 0.8%Clinic services 6.7%诊所服务 6.7%Membership fees 0.0%会员费 0.0%Others 1.4%其他 1.4%

Source: annual report 2025, page 174.出处:2025 年年报第 174 页。

Major events大事记

2022THKD launched Abbott GLP Total Lab Automation on 8 December.THKD 于 12 月 8 日启用 Abbott GLP Total Lab Automation。

Source: annual report 2023, page 14.出处:2023 年年报第 14 页。

2023The Oncology & Nuclear Medicine facility launched on 18 March.Oncology & Nuclear Medicine 设施于 3 月 18 日启用。

Source: annual report 2023, page 14.出处:2023 年年报第 14 页。

2023Thomson TCM opened a satellite clinic at ReU Living in October.Thomson TCM 于 10 月在 ReU Living 开设卫星诊所。

Source: annual report 2024, page 9.出处:2024 年年报第 9 页。

2023Barry Kan Kheong Ng was redesignated Executive Vice Chairman on 10 November.Barry Kan Kheong Ng 于 11 月 10 日调任执行副主席。

Source: annual report 2024, page 99.出处:2024 年年报第 99 页。

2024Dr. Heng Jun Li Melvin became Acting Group Chief Executive Officer on 29 January.Dr. Heng Jun Li Melvin 于 1 月 29 日出任代理集团首席执行官。

Source: annual report 2024, page 100.出处:2024 年年报第 100 页。

2024TMC Care discontinued its e-commerce platform in May.TMC Care 于 5 月停止运营其电子商务平台。

Source: annual report 2024, page 25.出处:2024 年年报第 25 页。

2024THSB signed a service provider agreement with OncoCare Medical Malaysia on 5 September for selected services at THKD's Oncology Centre.THSB 于 9 月 5 日与 OncoCare Medical Malaysia 签订服务供应商协议,为 THKD 的 Oncology Centre 提供指定服务。

Source: annual report 2024, page 18.出处:2024 年年报第 18 页。

2024Cheah Ho Chee retired on 6 November; Wan Nadiah Binti Wan Mohd Abdullah Yaakob was removed on 9 December.Cheah Ho Chee 于 11 月 6 日退休;Wan Nadiah Binti Wan Mohd Abdullah Yaakob 于 12 月 9 日被免职。

Source: annual report 2025, page 143.出处:2025 年年报第 143 页。

2025Dato’ Dr. Adzuan Abdul Rahman joined as Group Chief Executive Officer on 10 February.Dato’ Dr. Adzuan Abdul Rahman 于 2 月 10 日加入,担任集团首席执行官。

Source: annual report 2025, page 117.出处:2025 年年报第 117 页。

2025Thomson Fertility launched EndoCare@Thomson with the Endometriosis Association of Malaysia in February.Thomson Fertility 于 2 月与 Endometriosis Association of Malaysia 联合推出 EndoCare@Thomson。

Source: annual report 2025, page 25.出处:2025 年年报第 25 页。

2025The employee share option scheme expired on 28 May. All unexercised options lapsed, and the scheme committee was dissolved.员工购股权计划于 5 月 28 日到期。所有未行使的购股权失效,计划委员会也随之解散。

Source: annual report 2025, page 140.出处:2025 年年报第 140 页。

Revenue, profit and operating cash营业额、盈利与营运现金

Revenue营业额
2022
RM243.8m2.44亿令吉
2023
RM311.4m3.11亿令吉
2024
RM346.4m3.46亿令吉
2025
RM345.5m3.46亿令吉
Profit for the financial year本财政年度盈利
2022
RM41.4m4.14千万令吉
2023
RM39.3m3.93千万令吉
2024
RM40.6m4.06千万令吉
2025
RM3.61m361万令吉
Net cash from operating activities营运活动所得现金净额
2022
RM35.6m3.56千万令吉
2023
RM54.6m5.46千万令吉
2024
RM74.8m7.48千万令吉
2025
RM22.5m2.25千万令吉

Cash and borrowings现金与借款

Cash and bank balances现金与银行结余
2022
RM141.1m1.41亿令吉
2023
RM166.5m1.67亿令吉
2024
RM188.6m1.89亿令吉
2025
RM109.6m1.10亿令吉
Current borrowings流动借款
2022
RM10.0m1.00千万令吉
2023
RM17.7m1.77千万令吉
2024
RM25.3m2.53千万令吉
2025
RM39.9m3.99千万令吉
Non-current borrowings非流动借款
2022
RM200.4m2.00亿令吉
2023
RM201.4m2.01亿令吉
2024
RM179.9m1.80亿令吉
2025
RM143.0m1.43亿令吉

Assets and equity资产与权益

Total assets总资产
2022
RM1,132.8m11.33亿令吉
2023
RM1,176.8m11.77亿令吉
2024
RM1,189.7m11.90亿令吉
2025
RM1,132.2m11.32亿令吉
Total equity总权益
2022
RM827.4m8.27亿令吉
2023
RM862.0m8.62亿令吉
2024
RM888.0m8.88亿令吉
2025
RM853.0m8.53亿令吉

20232023 年

Operations generated RM54.6 million of cash. Cash paid for property, plant and equipment was RM32.0 million, and intangible assets cost RM2.5 million. The Group drew RM17.2 million of term loans and repaid RM7.6 million. Dividends paid were RM4.8 million. Cash and bank balances ended the year at RM166.5 million.营运带来 RM54.6 million 现金。购买产业、厂房与设备支付 RM32.0 million,购买无形资产支付 RM2.5 million。集团提取定期贷款 RM17.2 million,偿还 RM7.6 million。已付股息为 RM4.8 million。年末现金与银行结余为 RM166.5 million。

Source: annual report 2023, page 137.出处:2023 年年报第 137 页。

20242024 年

Operations generated RM74.8 million of cash. The Group paid RM25.4 million for property, plant and equipment and RM3.2 million for intangible assets. It placed RM31.1 million in deposits with financial institutions with original maturities above three months. Term loan drawings were RM3.0 million and repayments were RM15.1 million. Dividends paid were RM14.6 million. Cash and bank balances ended the year at RM188.6 million.营运带来 RM74.8 million 现金。集团购买产业、厂房与设备支付 RM25.4 million,购买无形资产支付 RM3.2 million。集团向金融机构存放原到期日超过三个月的存款 RM31.1 million。提取定期贷款 RM3.0 million,偿还 RM15.1 million。已付股息为 RM14.6 million。年末现金与银行结余为 RM188.6 million。

Source: annual report 2024, page 147.出处:2024 年年报第 147 页。

20252025 年

Operations generated RM22.5 million of cash. The Group paid RM40.7 million for property, plant and equipment and RM432,000 for intangible assets. It withdrew RM32.2 million from deposits with original maturities above three months. No term loan was drawn; RM22.6 million was repaid. Dividends paid were RM38.6 million. Cash and bank balances ended the year at RM109.6 million. Profit before tax was RM7.1 million and profit for the year was RM3.6 million. The report attributes the fall in profitability to discontinued contracts, higher-than-expected discounts, increased operating expenses and depreciation charges.营运带来 RM22.5 million 现金。集团购买产业、厂房与设备支付 RM40.7 million,购买无形资产支付 RM432,000。集团提取原到期日超过三个月的存款 RM32.2 million。集团没有提取定期贷款,偿还了 RM22.6 million。已付股息为 RM38.6 million。年末现金与银行结余为 RM109.6 million。税前盈利为 RM7.1 million,全年盈利为 RM3.6 million。年报将盈利下降归因于合约终止、折扣高于预期、营运开支增加及折旧费用。

Source: annual report 2025, pages 14, 157.出处:2025 年年报第 14、157 页。

Across the years跨年合看

Operating cash increased in 2024 and fell in 2025. Dividends paid increased in both years. Non-current borrowings fell, while current borrowings rose. Each report says no funds were raised through a corporate proposal during its financial year. The employee share option scheme expired on 28 May 2025, and all unexercised options lapsed.营运现金在 2024 年增加,在 2025 年下降。已付股息连续两年增加。非流动借款下降,流动借款上升。各份年报均表示,该财政年度没有通过企业融资方案筹集资金。员工购股权计划于 2025 年 5 月 28 日到期,所有未行使的购股权随之失效。

Source: annual report 2023, page 120; annual report 2024, page 130; annual report 2025, page 140.出处:2023 年年报第 120 页;2024 年年报第 130 页;2025 年年报第 140 页。

Still to be spent尚未支出的承诺

Capital expenditure approved and contracted for construction and purchases of property, plant and equipment was RM25.8 million in 2023, RM49.3 million in 2024 and RM29.6 million in 2025. The 2025 report says the previous share-issue mandate was unused and raised no proceeds.已批准并签约的建造及购买产业、厂房与设备资本支出,在 2023 年为 RM25.8 million,2024 年为 RM49.3 million,2025 年为 RM29.6 million。2025 年报表示,上一项发股授权未被使用,也没有筹得资金。

Source: annual report 2023, page 181; annual report 2024, page 191; annual report 2025, pages 200, 213.出处:2023 年年报第 181 页;2024 年年报第 191 页;2025 年年报第 200、213 页。

Four years of figures四年数字

Group figures, in RM thousand (×1,000), as printed in the statements.集团数字,单位千令吉(×1,000),照财务报表所印。

Group集团2022202320242025
RM'000千令吉RM'000千令吉RM'000千令吉RM'000千令吉
Revenue营业额243,774311,443346,418345,538
Profit before tax税前盈利32,18040,89052,6217,072
Profit for the financial year本财政年度盈利41,38939,25740,6483,606
Net cash from operating activities营运活动所得现金净额35,64754,57174,76322,506
Purchase of property, plant and equipment购买产业、厂房与设备(67,690)(31,962)(25,350)(40,707)
Dividends paid已付股息(3,858)(4,813)(14,628)(38,616)
Total assets总资产1,132,8501,176,7951,189,7231,132,190
Current borrowings流动借款10,03517,69125,30239,948
Non-current borrowings非流动借款200,407201,368179,932143,024
Cash and bank balances现金与银行结余141,135166,544188,572109,564
Total equity总权益827,388861,959888,034853,043

On a computer, hover over a figure for the report and page it is printed on.在电脑上把鼠标移到数字上,可看到它印在哪份年报的哪一页。

Said and done说过的与做到的

What the reports said年报说要做的What later reports show之后年报显示的Status状态
In 2024, the Board recommended a final dividend of 0.4898 sen per share and a special dividend of 1.7271 sen per share.2024 年,董事会建议派发每股 0.4898 仙终期股息及每股 1.7271 仙特别股息。The 2025 report records both dividends as paid on 3 January 2025, totalling RM38.6 million.2025 年报记载,两项股息已于 2025 年 1 月 3 日支付,合计 RM38.6 million。

Source: annual report 2024, page 10; annual report 2025, page 179.出处:2024 年年报第 10 页;2025 年年报第 179 页。

Paid已支付
The 2024 report described an upcoming rebranding of TMC Fertility to Thomson Fertility.2024 年报表示,TMC Fertility 即将更名为 Thomson Fertility。The 2025 report says the rebranding was initiated.2025 年报表示,更名工作已经启动。

Source: annual report 2024, page 23; annual report 2025, page 26.出处:2024 年年报第 23 页;2025 年年报第 26 页。

Started已启动
In 2024, TMC Fertility was exploring AI for selecting oocytes, sperm and embryos.2024 年,TMC Fertility 正探索将人工智能用于卵母细胞、精子及胚胎的筛选。The 2025 report describes AI being integrated into embryo grading.2025 年报记载,人工智能已被用于胚胎分级。

Source: annual report 2024, page 22; annual report 2025, page 24.出处:2024 年年报第 22 页;2025 年年报第 24 页。

Used for embryo grading已用于胚胎分级
In 2024, the Group planned to expand referral centres in Vietnam and Indonesia.2024 年,集团计划扩展越南及印度尼西亚的转介中心。The 2025 report records a Representative Office established in Jakarta for patient referrals. It does not report a referral centre opening in Vietnam.2025 年报记载,集团已在雅加达设立代表处,负责患者转介。年报没有记载越南转介中心开业。

Source: annual report 2024, page 18; annual report 2025, pages 22, 24.出处:2024 年年报第 18 页;2025 年年报第 22、24 页。

Jakarta office established; Vietnam opening not reported雅加达代表处已设立;未报告越南中心开业
The 2024 report aimed to establish a Scope 1 and Scope 2 emissions baseline by FY2025.2024 年报的目标是在 2025 财政年度前建立范围一及范围二排放基准。The 2025 report says a baseline for Scope 1 and Scope 2 emissions intensity was established.2025 年报表示,已建立范围一及范围二排放强度基准。

Source: annual report 2024, page 59; annual report 2025, page 78.出处:2024 年年报第 59 页;2025 年年报第 78 页。

Emissions intensity baseline established已建立排放强度基准
In 2024, Hospital Iskandariah was planned for phased completion and full operation by 2030.2024 年,Hospital Iskandariah 计划分阶段完工,并于 2030 年前全面运营。The 2025 report continues to describe phased completion and retains the target of full operation by 2030.2025 年报仍说明项目将分阶段完工,并保留于 2030 年前全面运营的目标。

Source: annual report 2024, page 15; annual report 2025, pages 17, 19.出处:2024 年年报第 15 页;2025 年年报第 17、19 页。

Still planned for 2030仍以 2030 年为目标

What the reports leave open年报留下待看的事

  • Hospital Iskandariah remains a development project with full operation targeted by 2030. The latest property list still describes the Johor Bahru development land as vacant.Hospital Iskandariah 仍是开发项目,目标为于 2030 年前全面运营。最新产业清单仍将新山的开发土地列为空地。

    Source: annual report 2025, pages 19, 206.出处:2025 年年报第 19、206 页。

  • Approximately 21.8% of loans and borrowings mature within one year. The loan covenants include debt-to-equity, debt service cover and security cover requirements. The report says there was no indication of difficulty complying at the reporting date.约 21.8% 的贷款与借款在一年内到期。贷款契约包含债务权益比率、偿债覆盖率及担保覆盖率要求。年报表示,在报告日没有迹象显示履约存在困难。

    Source: annual report 2025, pages 193, 202.出处:2025 年年报第 193、202 页。

  • Net trade receivables aged more than 60 days were RM5.4 million. Ten customers accounted for approximately 64% of gross trade receivables at year end.账龄超过 60 天的贸易应收款净额为 RM5.4 million。年末十名客户占贸易应收款总额约 64%。

    Source: annual report 2025, pages 188, 204.出处:2025 年年报第 188、204 页。

  • The proposed FY2025 final dividend is 0.1863 sen per share. The notice says payment on 6 January 2026 depends on shareholder approval.拟派的 2025 财政年度终期股息为每股 0.1863 仙。通告表示,须经股东批准,才会于 2026 年 1 月 6 日支付。

    Source: annual report 2025, pages 15, 211.出处:2025 年年报第 15、211 页。

Facts as printed in the company's annual reports, with the page of each; no rating and no advice. Built 2026-10-28.内容为公司年报所印的事实,并注明页码;不评级,不构成投资建议。生成日期 2026-10-28。